MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment - Data from a pilot study using IO Loop™ with TheraSphere® (a 90Y transarterial radioembolisation therapy) will be presented at the World Conference on Interventional Oncology - HealthLoop.com / TheraSphere.com / BTG-IM.com
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment

 

NewswireToday - /newswire/ - London, United Kingdom, 2017/05/19 - Data from a pilot study using IO Loop™ with TheraSphere® (a 90Y transarterial radioembolisation therapy) will be presented at the World Conference on Interventional Oncology - HealthLoop.com / TheraSphere.com / BTG-IM.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, a global specialist healthcare company, and HealthLoop, a cloud-based platform that automates follow-up patient care, announced today their collaboration on IO Loop™. This is an exclusive service from BTG that gives access to a turn-key digital support platform powered by Healthloop. IO Loop™ enables patients and their physicians to stay connected, providing improved pre-procedural patient instructions and ongoing follow-up care outside of the acute care setting. This service also provides the care team with patient-reported outcomes that help physicians meet the new reporting requirements of Medicare Access and CHIP Authorisation Act (MACRA).

Patients are the most underleveraged resource in the achievement of better health outcomes. IO Loop™ empowers patients by connecting them with their physician via a digital support platform, and fully engages them in their treatment journey. Online engagement before, during and after treatment has the potential to reduce physician burden, delivering the right information at the right time. The IO Loop™ service helps patients prepare for their treatment, track and report any symptoms, review key treatment information at the appropriate time, and provides a personalised follow-up care plan with appropriate advice. This support results in a better overall patient experience.

Lisa Hayden, Vice President, Global Reimbursement at BTG commented: “We know that patients who are involved in their treatment journey have the best chance of better outcomes, and at BTG we are committed to providing solutions to achieve this. Through IO Loop™, the first service of its kind in interventional oncology, automated collection of patient information, improved patient outcomes, and potentially enhanced patient experiences can have unique benefits for healthcare providers and help them to meet the reporting requirements of MACRA.”

Todd Johnson, HealthLoop CEO said of the partnership: “At HealthLoop our mission is to keep physicians and patients connected via our proven technology-enabled engagement platform. By partnering with BTG on this important initiative we believe that we can empower patients and offer the best experience both for them and their healthcare provider.”

The collaboration leverages BTG’s leadership in interventional oncology with HealthLoop’s digital expertise in patient-centric solutions, offering a unique service that has the potential to differentiate and simplify interventional oncology practice.

Karen Grace, Clinical Nurse Coordinator, Interventional Oncology at Northwestern Memorial Hospital, Chicago commented: “At Northwestern we have experienced the benefits of the IO Loop™ service first hand. Having ongoing access to the patient’s performance has enabled timely intervention, which in turn has minimised complications and reduced the likelihood of re-admission. This not only improves the quality of life of our patients but also enables us, as healthcare providers, to deliver a higher standard of care.”

Data showing the benefits of this technology with TheraSphere® in interventional oncology will be presented next month at the World Conference on Interventional Oncology (WCIO) in Boston, U.S., 8-11 June 2017.

About BTG Interventional Oncology
BTG Interventional Oncology (btg-im.com) is transforming the way cancer is treated with wide-ranging solutions consisting of minimally-invasive, highly targeted therapies that can be personalized to each patient’s needs. Our products are used to treat or provide symptomatic relief for people with cancer and benign tumors.

About HealthLoop
HealthLoop (healthloop.com) engages patients at home before their admission and for weeks and months after discharge to continuously guide, educate, and assess the status of their recovery. By automatically sending notifications to patients, HealthLoop remotely monitors patients and identifies those that need help, allowing clinical teams to proactively intervene before costs and complications escalate. Developed as an enterprise solution to support all clinical specialties, HealthLoop’s content and analytics are deeply integrated into care management workflows. HealthLoop facilitates over 500,000 patient interactions every month.

About TheraSphere®
TheraSphere® 90Y glass microspheres (therasphere.com) are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy, delivering high doses of radiation to liver tumors while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies. In the EU, Singapore, South Korea and Canada, TheraSphere® is approved for the treatment of hepatic neoplasia. In the US, TheraSphere® is approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment. The effectiveness of this device for this use has not been demonstrated.

Contact: Jonathan Falcone - Media Liaison
P: +44(0)20 8618 2752 / M: +44(0)78 2523 8898

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Huntington Study Group Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)